Insulin - Analogs & derivatives
Research News and Information

Saturday, November 21, 2009

A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial).

30 Oct 2009 PURPOSE: To study glycemic control and hypoglycemia development upon initiation of insulin through a self-titration schedule in a 24-week trial, conducted with 4875 insulin-naïve patients with poorly controlled type 2 diabetes, predominantly in a ... Read more...

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

5 Oct 2009 CONTEXT: National public insurance for drugs is often based on evidence of comparative effectiveness and cost-effectiveness. This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been ... Read more...

Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes.

29 Sep 2009 OBJECTIVE: To report a case of leukocytoclastic vasculitis associated with insulin aspart therapy. CASE SUMMARY: A 56-year-old man was admitted to the Department of Endocrinology because of a poorly controlled Type 2 diabetes. In an attempt to reach ... Read more...

Latest indexed articles for 'Insulin - Analogs & derivatives'

These are the very latest articles for this heading:

• Images in clinical medicine. Injection-site lipoatrophy. 3 Nov 2009
• A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). 30 Oct 2009
• Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. 5 Oct 2009
• Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes. 29 Sep 2009
• Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. 29 Sep 2009
• Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. 14 Sep 2009
• A draft at the back door. 30 Aug 2009
• [Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart] 28 Aug 2009
• Insulin glargine (Lantus) and cancer risk. 22 Aug 2009
• Insulin glargine and cancer: another side to the story? 13 Aug 2009
• Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. 12 Aug 2009
• Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). 2 Aug 2009
• Insulin pump therapy for type 1 diabetes treatment in a girl with Down's syndrome. 30 Jul 2009
• Human insulin A-chain peptide analog(s) with in vitro biological activity. 30 Jul 2009
• Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. 30 Jul 2009
• Efficacy of insulin glargine in perioperative glucose control in type 2 diabetic patients. 30 Jul 2009
• [How to calm diabetic patients? About the difficulty of counting to 4] 21 Jul 2009
• ["Educating patients about the study"] 21 Jul 2009
• [Depot insulin with tumor risk. Changing now or staying cool? (interview by Sarah Pampel)] 21 Jul 2009
• Insulin glargine and malignancy: an unwarranted alarm. 15 Jul 2009

See a longer list of these articles.

Technical information about 'Insulin'

Definition: A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).

Chemical name: Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-

Registry Number: 11061-68-0

Descriptor UI: D007328

Alternative terms: Insulin; Insulin, Regular; Regular Insulin; Humulin S; Iletin; Insulin A Chain; Insulin, Globin Zinc; Globin Zinc Insulin; Velosulin; Insulin, Regular, Human; Insulin, Regular, Pork; Novolin; Sodium Insulin; Insulin, Sodium; Type I Insulin; Insulin, Type I; Type II Insulin; Insulin, Type II; Humulin; Insulin, Regular, Beef-Pork;

Related Mesh Headings: Hyperinsulinism; Nonsuppressible Insulin-Like Activity; Proinsulin; Receptor, Insulin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Hypoglycemic Agents;

Tree Number: D06.472.699.587.740.625; D12.644.548.586.740.625;

Technical Notes: /blood: consider also HYPERINSULINEMIA (excessively high blood insulin levels) but do not confuse with HYPERINSULINISM (excessive secretion of insulin by pancreas); /immunology: consider also INSULIN ANTIBODIES; precursor = PROINSULIN; INSULIN INFUSION SYSTEMS is available